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Aggregated filamentous forms of hyperphosphorylated tau (a microtubule-associated protein) represent pathological hallmarks of
Alzheimer’s disease (AD) and other tauopathies.While axonal transport dysfunction is thought to represent a primary pathogenic factor
in AD and other neurodegenerative diseases, the direct molecular link between pathogenic forms of tau and deficits in axonal transport
remain unclear. Recently, we demonstrated that filamentous, but not soluble, forms of wild-type tau inhibit anterograde, kinesin-based
fast axonal transport (FAT) by activating axonal protein phosphatase 1 (PP1) and glycogen synthase kinase 3 (GSK3), independent of
microtubule binding. Here, we demonstrate that amino acids 2–18 of tau, comprising a phosphatase-activating domain (PAD), are
necessary and sufficient for activation of this pathway in axoplasms isolated from squid giant axons. Various pathogenic forms of tau
displaying increased exposure of PAD inhibited anterograde FAT in squid axoplasm. Importantly, immunohistochemical studies using
a novel PAD-specific monoclonal antibody in human postmortem tissue indicated that increased PAD exposure represents an early
pathogenic event in AD that closely associates in time with AT8 immunoreactivity, an early marker of pathological tau. We propose a
model of pathogenesis in which disease-associated changes in tau conformation lead to increased exposure of PAD, activation of PP1-
GSK3, and inhibitionof FAT.Results from these studies reveal a novel role for tau inmodulating axonal phosphotransferases andprovide
a molecular basis for a toxic gain-of-function associated with pathogenic forms of tau.
Introduction
Aggregates of the microtubule-associated protein tau represent
major pathological components in Alzheimer’s disease (AD) and
other tauopathies (Grundke-Iqbal et al., 1986;Wood et al., 1986)
and correlate with progressive cognitive decline in AD (Kosik et
al., 1986; Arriagada et al., 1992; Giannakopoulos et al., 2003). The
identification of tau mutations in hereditary tauopathies directly
link tau to neurodegeneration (Goedert and Jakes, 2005). How-
ever, the molecular mechanisms behind tau-mediated toxicity
remain unclear.
Axonal transport dysfunction is implicated as a critical patho-
genic factor in AD and other neurodegenerative diseases (Roy et
al., 2005; Morfini et al., 2009). Experiments in isolated squid
axoplasm revealed that aggregated WT tau selectively inhibited
kinesin-based anterograde fast axonal transport (FAT) at physi-
ological levels, while soluble WT tau monomers did not, even at
concentrations 10-fold higher than physiological levels
(LaPointe et al., 2009; Morfini et al., 2009). The toxic effect of
aggregated tau on anterograde FAT involved activation of protein
phosphatase 1 (PP1) and glycogen synthase kinase 3 (GSK3)
(LaPointe et al., 2009). Deletion experiments suggested that this
effect required amino acids 2–18 of tau (LaPointe et al., 2009).
However, these studies did not explain why monomeric, soluble
tau did not inhibit FAT.
Findings on the conformationof soluble tauprovided apotential
explanation for this apparent paradox. Originally, tau was consid-
ered a “natively unfolded” protein with little secondary structure in
solution (Schweers et al., 1994). However, recent fluorescence reso-
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nanceenergy transfer studies suggest that solubleWTtaumonomers
adopt a “paperclip” conformation involving close interactionsof the
C terminus with themicrotubule binding repeats (MTBRs) and the
N terminuswith theC terminus (Jeganathan et al., 2006). Patholog-
ical forms of tau appear to alter the paperclip conformation. For
example, the AT8 phosphoepitope (Ser199/Ser202/Thr205) found
inAD and other tauopathies reduced folding of theN terminus into
thepaperclip conformation (Jeganathan et al., 2008). Similarly, a tau
mutation in a patient with inherited frontotemporal dementia
(FTD) results in deletion of the “hinge” region that is crucial for
N-terminal folding (Rovelet-Lecrux et al., 2009), rendering thismu-
tant tau protein incapable of assuming the paperclip conformation.
Theseobservations suggest thatdisease-associated taumodifications
disrupt the paperclip conformation, but molecular mechanisms
linking disruptions in tau conformation to inhibition of FAT re-
mained unknown.
We present evidence indicating that disease-associated mod-
ifications in tau that impair the paperclip conformation inhibit
anterograde FAT. Results from our experiments suggest that
amino acids 2–18 of tau, a domainwe refer to as the phosphatase-
activating domain (PAD), represent a biologically active protein
motif capable of activating the PP1–GSK3 pathway. The rele-
vance of these findings to AD was validated using a novel PAD-
specific antibody to document increased PAD exposure early in
the course of disease. Based on these results, we propose a model
of pathogenesis where modifications in tau, including aggrega-
tion, hyperphosphorylation, and FTD-associatedmutation all re-
sult in increased PAD exposure, activation of the PP1–GSK3
pathway, and inhibition of anterograde FAT. Collectively, our
findings provide a commonmolecular basis for the toxic gain-of-
function mechanism associated with biochemically distinct
disease-related modifications of tau.
Materials andMethods
Reagents. The following reagents were pur-
chased from commercial vendors: okadaic acid
(catalog #495604, EMDChemicals) and inhib-
itor 2 (I-2; catalog #539638, EMD Chemicals);
PAD peptide (amino acids 2–18) and scram-
bled PAD peptide (both with 98% purity)
(GenScript); and Complete, EDTA-free Pro-
tease Inhibitor tablets (catalog #11873580001,
Roche). ING-135 (Kozikowski et al., 2007) was
a generous gift from Dr. A. Kozikowski (Uni-
versity of Illinois at Chicago, Chicago, IL).
Recombinant tau proteins. Tau proteins are
numbered according to the largest adult hu-
man isoform (ht40; 441 aa) in the CNS. Full-
length ht40 (WT tau) was generated from
previously described pT7c plasmids (Fig. 1A)
(LaPointe et al., 2009). Site-directed mutagen-
esis (QuikChange II Kit, catalog #200524,
Stratagene) was used to create point mutations
in full-length tau constructs. Ser199, Ser202,
and Thr205 were mutated to glutamic acid (E)
to create the AT8 pseudophosphorylated mu-
tant protein (AT8 tau) (Fig. 1B). Amino acids
144–273 (144–273 tau) (Fig. 1C) were de-
leted by inserting EcoRV restriction sites flank-
ing the appropriate region of the cDNA.
Following EcoRV digestion and T4 ligation
(NewEngland Biolabs; used according toman-
ufacturer’s instructions), the remaining EcoRV
site was removed via deletion using the Site-
DirectedMutagenesis Kit described above. The
6D tau and 6P tau constructs were generated
from previously described pT7c plasmid cD-
NAs (Fig. 1D,E) (Luo et al., 2004; LaPointe et al., 2009). A 6D protein
with amino acids 2–18 deleted ( 2–18 6D tau) (Fig. 1F) was created by
restriction digestion and ligation of 6D and 2–18 tau cDNAs, both of
which have been described previously (LaPointe et al., 2009). The tau
cDNA plasmid constructs were amplified in XL-1 blue supercompetent
Escherichia coli, purified with the Qiagen Miniprep kit, and cDNA se-
quenceswere verified byDNA sequencing. T7 express supercompetentE.
coli cells were used to express tau constructs, and the proteins were pu-
rified through His-tag high-affinity resin and size exclusion chromatog-
raphy as previously described (Carmel et al., 1996).
Squid axoplasmmotility assay. Freshly extruded axoplasms from squid
giant axons (Loligo pealii; Marine Biological Laboratory, Woods Hole,
MA) were used to measure axonal transport, as described previously
(Morfini et al., 2007; LaPointe et al., 2009). Tau proteins were diluted in
X/2 buffer (175 mM potassium aspartate, 65 mM taurine, 35 mM betaine,
25 mM glycine, 10 mM HEPES, 6.5 mM MgCl2, 5 mM EGTA, 1.5 mM
CaCl2, 0.5 mM glucose, and 10 mM ATP, pH 7.4) and perfused into
isolated axoplasms at a final concentration of 2M.Use of tau proteins at
2Mwas specifically chosen since this is within the physiological levels of
tau in brains (Alonso et al., 1996; King et al., 1999) and is within the
physiological range of tau monomer/tubulin dimer ratios (Drubin et al.,
1985; Morfini et al., 2007; LaPointe et al., 2009). A Zeiss Axiomat micro-
scope equipped with a 100 objective (1.3 numerical aperture) and dif-
ferential interference contrast optics, equipped for digital video
processing and analysis was used to visualize vesiclemotility (Brady et al.,
1993). Anterograde and retrograde transport were measured by match-
ing vesicle speed to calibrated cursors over 50min as described previously
(Brady et al., 1993; Morfini et al., 2002b).
Preparation of 32P-radiolabeled phosphatase substrate and phospha-
tase assay in squid axoplasm. Recombinant GST-c-Jun (75 g) was
incubated with 10 g of recombinant p38 (a generous gift from Dr.
D. Bosco, University of Massachusetts, Amherst, MA) in the presence
of 100 M 32P-radiolabeled ATP in a 20 l volume. After 1 h at 30°C,
Figure 1. Schematic diagram of the tau constructs used. A, Full-length wild-type ht40 (WT tau) is the largest isoform of tau
found in the adult CNS. WT tau contains the PAD motif corresponding to amino acids 2–18 (black box), two alternatively spliced
N-terminal exons (E2 and E3), and MTBRs 1–4. B, The AT8 tau protein was pseudophosphorylated at S199, S202, and T205 by
mutagenesis of S3 E and T3 E to mimic the phosphoepitope recognized by the AT8 antibody (Biernat et al., 1992; Goedert et
al., 1995) in hyperphosphorylated tau. C, The144–273 tau mutant protein corresponds to a deletion of amino acids 144–273
(the proline-rich region andMTBR1) thatwas found in a patientwith an autosomal-dominant familial formof FTD (Rovelet-Lecrux
et al., 2009). D, The 6D tau protein is a noncanonical N-terminal isoform containing amino acids 1–143 with an additional 11
unique C-terminal amino acids (Luo et al., 2004). E, The 6P protein is the same as 6D, except the last 11 C-terminal amino acids are
different (Luo et al., 2004). F, The2–18 6D protein has amino acids 2–18 deleted from the N terminus. G, Synthetic peptide
composed of the PAD sequence (amino acids 2–18 fromWT tau). H, Synthetic peptide composed of the same amino acids as the
PAD peptide, but rearranged in a random order.
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the resulting 32P-c-Jun samples were stored at 20°C until used in
phosphatase assays.
First, a control experiment was run to confirm that endogenous axo-
plasmic phosphatases could dephosphorylate 32P-c-Jun. Squid axoplasm
was incubated with 32P-c-Jun (1 g) for 0 min (input) or 30 min (con-
trol), and with okadaic acid (1 M) or I-2 (400 nM) for 30 min. To
determine whether PAD affects phosphatase activity, sister axoplasms
were extruded on coverglasses and perfused with 35 l of either PAD or
scrambled PAD peptides (10 M each) in buffer X/2 supplemented with
1mMATP plus 1g of 32P-cJun. A 4l aliquot of perfusate was removed
at 10, 20, and 30 min, and was transferred to tubes containing 9 l of
sample buffer. Samples were run by SDS-PAGE, the gels were dried, and
32P incorporation in GST-cJun was analyzed with the Typhoon
PhosphorImager.
Kinase assay in isolated squid axoplasm. Sister axoplasmswere extruded
on coverglasses and perfused with 30l of either PAD or scrambled PAD
peptides (10 M) in buffer X/2 supplemented with 1 mM ATP. After 45
min of incubation, 12 l aliquots of perfusate containing solubilized
axoplasmic proteins were removed from each axon; diluted to 80l with
20mMHEPES, pH7.4, 3mMEDTA, 2Mokadaic acid, and 1/80 protease
inhibitor mixture (P8340, Sigma); and kept on ice. Aliquots of diluted
perfusates (20l) were supplementedwith either 200MGSK3 substrate
peptide (GSM, catalog #12-533, Millipore) or with 50 M myristoylated
alanine-rich C-kinase substrate (MARCKS) (catalog #454880, Calbio-
chem), and the final volume adjusted to 32 l with 20 mM HEPES, pH
7.4. Kinase reactions were started by adding 8l of 5X kinase buffer (100
mM HEPES, pH 7.4, 250 mM K aspartate, 50 mM MgCl2, and 500 M
32P-radiolabeled ATP). After 30min of incubation at room temperature,
aliquots were spotted on P81 cellulose paper in duplicate. Papers were
washed three times in 100 mM phosphoric acid, and 32P incorporation
into peptides was measured by scintillation counting. GSK3 activity was
expressed as the ratio of incorporation between GSM and MARCKS
peptides for each condition.
Monoclonal antibody production. Mouse monoclonal anti-
bodies were raised against a synthetic PAD peptide
(C 2AEPRQEFEVMEDHAGTY18) conjugated to KLH (GenScript) as
previously described (Reyes et al., 2008). Briefly, BALB/c female mice
(catalog #001026, Jackson Laboratories) were immunized subcutane-
ously with peptides every 21 d over a 5 month period; splenocytes were
then removed and fused to SP2/o myeloma cells. Positive clones that
reacted specifically with PAD by ELISA analysis (Reyes et al., 2008) were
selected, and then subcloned four times at limiting dilutions and isotyped
[tauN-terminal 1 (TNT1) is an IgG1]. Antibody production was accom-
plished in a CELLine Classic 1000 bioreactor (DC-90005, Sartorius AG)
before proteinA purification at high pH. The sensitivity and specificity of
the TNT1 antibody for PAD in tau was assessed using ELISAs andWest-
ern blotting (see Fig. 7A).
Tau isolation fromhuman brain tissue. Fresh frozen frontal cortex from
control (n  4) and severe AD (n  5) brains was obtained from the
Brain Bank of the Cognitive Neurology and Alzheimer’s Disease Center
at Northwestern University. Heat-stable/acid-soluble tau was extracted
based on protocols described before (Reyes et al., 2008). Sarkosyl-
insoluble tau [paired helical filaments (PHF)] and Sarkosyl-soluble tau
were obtained using methods similar to those in previous reports (Hase-
gawa et al., 1992).
Western and dot blots. ForWestern blot analysis, soluble and insoluble
tau samples were separated by 10% SDS-PAGE and transferred to nitro-
cellulosemembranes, as described previously (Reyes et al., 2008). For dot
blots, soluble and insoluble tau samples were spotted directly onto nitro-
cellulose membranes (LaPointe et al., 2009). Both Western and dot blot
membranes were blocked with 2% nonfat dry milk in Tris-buffered sa-
line (TBS), pH7.4, and incubated in primary antibodies overnight at 4°C.
The Tau12 (Horowitz et al., 2004) and TNT1 mouse monoclonal anti-
bodies were diluted from 1 mg/ml purified stock solutions to 1:500,000
and 1:300,000, respectively. The rabbit polyclonal antibody, R1 tau
(Berry et al., 2004), was diluted 1:300,000 from a 1 mg/ml stock. After
rinsing, the membranes were incubated in peroxidase-conjugated horse
anti-mouse secondary antibody (PI-2000, Vector Laboratories) for 1 h at
room temperature. Reactivity was visualized using ECL substrate
(PI32106, Pierce), andWestern blots were visualized on Kodak Bio-max
XAR film, while dot blots were imaged on the Kodak Imaging Station
4000R for quantification of signal intensity. Data are expressed as the
ratio of TNT1/Tau12 intensity.
TNT1 immunohistochemistry. Tissue sections (40 m thick) from the
entorhinal cortex, hippocampus, inferior temporal gyrus, and superior
temporal gyrus of control (Braak stages I–II; n 4) and severe AD (Braak
stages V–VI; n 4) cases were obtained through the Cognitive Neurol-
ogy and Alzheimer’s Disease Center at Northwestern University. All sec-
tions were stained simultaneously to reduce variability in tissue
processing. Sections were processed as previously described (Kanaan et
al., 2007). The TNT1 primary antibody was diluted 1:400,000 (from 1
mg/ml stock) and incubated with the tissue sections overnight at 4°C.
The tissue was incubated in biotinylated goat anti-mouse secondary an-
tibody (diluted 1:500; BA-9200, Vector Laboratories) for 2 h, followed by
incubation inABC solution (PK-6100, Vector Laboratories; used accord-
ing to manufacturer’s instructions) for 1 h. The staining was developed
with 3,3-diaminobenzidine (D5637, Sigma). All stepswere performed at
room temperature unless otherwise noted, and each step was followed by
6 10 min rinses in TBS-0.5% Triton X-100. After developing the stain,
the tissue sections were mounted and coverslipped. Images were taken
using a Nikon Eclipse 90i microscope equipped with a DS-Ri1 camera
and Nikon Elements AR 3.10 software. Figures were generated using
Adobe Photoshop.
TNT1 and AT8 double-label immunofluorescence. Tissue sections (as
described above) from the hippocampus of control (Braak stages I–II;
n 4),mildAD (Braak stages III–IV; n 5), and severeAD (Braak stages
V-VI; n 4) cases were processed for double-label immunofluorescence
using TNT1 and the AT8 antibody (Biernat et al., 1992; Goedert et al.,
1995). All sections were stained simultaneously using similar methods as
previously described (Kanaan et al., 2007) to reduce variability in tissue
processing. The TNT1 primary antibody was diluted 1:40,000 (from 1
mg/ml stock) and incubated with the tissue sections overnight at 4°C.
The tissue was incubated in Alexa Fluor 594 goat anti-mouse IgG1
-chain-specific secondary antibody (diluted 1:500; A21125, Invitrogen)
for 2 h, followed by blocking uncomplexed secondary antibody sites with
10%mouse serum for 1 h. Then the sections were incubated overnight at
4°C with biotinylated AT8 antibody (MN1020B, Thermo Scientific) di-
luted at 1:1000. The AT8 antibody was labeled with Alexa Fluor 488-
conjugated streptavidin (diluted 1:500; S11223, Invitrogen) for 2 h.
Sections were mounted and coverslipped using Vectashield Hardest
(H-1400, Vector Laboratories). All steps were performed at room
temperature unless otherwise noted, and each step was followed by
6 10 min rinses in TBS-0.5% Triton X-100. Images were taken using
a fluorescence-equipped Nikon Eclipse 90i microscope with a
Q-imaging Retiga-SRV Fast1394 camera and Nikon Elements AR 3.10
software (with live deblur function). Figures were generated using
Adobe Photoshop.
Statistics.Each experimentwas repeated at least three times (see figures
for n values). Comparisons of vesicle motility rates were made using an
unpaired t test or a one-way ANOVA, as indicated. The WT tau mono-
mer group was used as the control group since no changes in motility
rates are observed in this group compared with unperfused axoplasms
(Morfini et al., 2007; LaPointe et al., 2009).Whenoverall significancewas
reached, the Student–Newman–Keuls post hoc analysis was used tomake
all possible comparisons. Kinase assays with results were compared using
a paired t test (paired by sister axoplasms). Significance was set at p 
0.01 or p 0.05, as indicated. SigmaStat software (Systat Software) was
used for all statistical tests.
Results
6D and 6P tau isoforms inhibit anterograde FAT
The isolated squid axoplasm is an ex vivo model system that al-
lows for direct, quantitative evaluation of different effectors on
anterograde (conventional kinesin-dependent) and retrograde
(cytoplasmic dynein-dependent) FAT rates by videomicroscopy.
When isolated axoplasm is perfused with aggregated tau, but
not soluble tau monomers, there is a selective inhibition of
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anterograde FAT through an N-terminal-mediated mecha-
nism involving activation of a PP1–GSK3 pathway, phosphor-
ylation of kinesin light chains, and dissociation of kinesin-1
from its transported cargoes (Morfini et al., 2004; LaPointe et
al., 2009).
To explore the N-terminal dependence of tau-mediated FAT
inhibition, we used the noncanonical N-terminal 6D and 6P tau
isoforms (Fig. 1D,E). Both 6D and 6P are identical to WT tau
from amino acids 1–143, but lack the proline-rich region, the
MTBRs, and C terminus of full-length tau, and each protein con-
tains a unique C-terminal 11 aa sequence (Luo et al., 2004; An-
dreadis, 2005). Thus, the 6D/6P isoforms can be used as
physiological tools for the evaluation of the N terminus of tau in
isolation from other functional domains and independent of mi-
crotubule binding or self-aggregation because both of these pro-
cesses require the MTBRs.
Vesicle motility assays in isolated axoplasm confirmed and
expanded our initial results with the N-terminal isoforms of tau.
As previously reported (Morfini et al., 2007; LaPointe et al.,
2009), perfusion of full-length WT tau monomers (2 M) (Fig.
1A) had no effect on FAT in squid axoplasm (Fig. 2A), while 6D
and 6P taumonomers (2M) significantly inhibited anterograde
FAT when compared withWT tau monomer (Fig. 2B,C) or buf-
fer controls (data not shown). Neither 6D nor 6P tau (Fig. 2D)
had an effect on retrograde FAT. Together, these data indicate
that the proline-rich region, MTBRs, and the C terminus of full-
length tau, as well as the unique 11 aa C termini of 6D and 6P do
not play a role in inhibiting anterograde FAT. Since similar levels
of FAT inhibition were obtained with 6D and 6P constructs (Fig.
2C,D), which are identical in the first 143 aa, we chose to focus on
the 6D tau for further experimentation.
6D Tau inhibits FAT by activating a PP1–GSK3
signaling cascade
Results from our previous work (LaPointe et al., 2009) prompted
us to evaluate whether aggregated tau and 6D tau inhibited an-
terograde FAT through a common mechanism. To this end, we
coperfused axoplasms with 6D tau and pharmacological inhibi-
tors of either PP1 or GSK3. Coperfusion of 6D tau with I-2 (50
nM), a specific PP1 inhibitor, completely prevented the effects of
6D tau on anterograde FAT (Fig. 3A,C). Similarly, coperfusion of
6D tau with okadaic acid (200 nM), a less specific inhibitor of the
major serine/threonine phosphatases (including both PP1 and
PP2), prevented the inhibition of anterograde FAT elicited by 6D
and 6P tau (data not shown). Furthermore, coperfusion of 6D tau
and the GSK3-specific pharmacological inhibitor ING-135 (100
nM) (Kozikowski et al., 2007; LaPointe et al., 2009) completely
blocked the inhibitory effects of 6D tau on anterograde FAT (Fig.
3B,C). Retrograde transport was not significantly affected in any
experiment (Fig. 3D). Together, these data demonstrate that, as
posited for aggregated tau (LaPointe et al., 2009), short
N-terminal isoforms of tau inhibit anterograde FAT by a mech-
anism involving activation of PP1 and GSK3 that is independent
of microtubule binding.
PAD is necessary and sufficient for anterograde
FAT inhibition
Aggregated tau lacking amino acids 2–18 or PAD (2–18) did not
inhibit anterograde FAT (LaPointe et al., 2009), suggesting that
this domain plays a critical role in the activation of the PP1–GSK3
pathway. To determine whether this domain mediates the inhib-
itory effects of 6D tau monomer on FAT, axoplasms were per-
fusedwith a recombinant 6D tau protein lacking PAD (2–18 6D
tau; 2 M) (Fig. 1F). As observed with 2–18 tau aggregates
(LaPointe et al., 2009), monomeric 2–18 6D tau showed no
Figure 2. N-terminal tau isoforms 6D and 6P tau selectively inhibit anterograde FAT. A–D,
Vesiclemotility assays in isolated squid axoplasm. Individual velocity (micrometers per second)
rate measurements (arrowheads) are plotted as a function of time (in minutes). Black arrow-
heads and lines represent anterograde FAT rates (conventional kinesin-dependent), and gray
arrows and lines represent retrograde FAT rates (cytoplasmic dynein-dependent). A, Perfusion
with soluble wild-type tau monomers (WT tau) did not affect FAT rates in the anterograde
(black triangle) or retrograde (gray triangle) direction.B, In contrast, soluble 6D taumonomers,
which cannot bindmicrotubules, selectively inhibited the rate of anterograde FAT, while retro-
grade FAT was not significantly affected. C, Quantitative analysis of FAT demonstrates that 6D
and 6P (n 5) tau caused a significant reduction in anterograde FATwhen comparedwithWT
taumonomers (*p0.01, unpaired t test).D, Retrograde FATwasunaffectedby6Dand6P tau.
Figure 3. 6D tau inhibits anterograde FAT via activation of a PP1–GSK3 cascade. A, Coper-
fusion of 6D tau and I-2, a specific PP1 inhibitor, prevented inhibition of anterograde (black
triangle) FAT elicited by 6D (compare with Fig. 2B). B, Coperfusion of 6D tau and ING-135, a
specific GSK3 inhibitor, similarly prevented inhibition of anterograde FAT. C, Quantitative anal-
ysis of FAT shows that inhibition of PP1 (via I-2) or inhibition of GSK3 (via ING-135) completely
prevents the anterograde FAT inhibition elicited by 6D tau (one-way ANOVA, *p 0.01 versus
WT Tau, 6DI-2, 6DING-135).D, Retrograde FAT (gray triangle, retrograde) was unaffected
by 6D, regardless of whether inhibitors were present.
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effect on FAT (Fig. 4A,D), demonstrating
that PAD is necessary for 6D tau-
mediated inhibition of anterograde FAT.
We next sought to determine whether
PAD is sufficient to induce anterograde
FAT inhibition or whether other tau do-
mains are also required. Isolated axo-
plasms were perfused with a synthetic
PAD peptide (AEPRQEFEVMEDHAGTY)
(Fig. 1G) or with a scrambled control
PAD peptide (AQEMDRVYEGEAPH-
TFE) (Fig. 1H) at the same concentration
(2 M). The PAD peptide selectively in-
hibited anterograde FAT (Fig. 4B,D), but
not retrograde FAT (Fig. 4B,E). In con-
trast, the scrambled PAD peptide had no
effect on FAT in either direction (Fig. 4C–
E). Together, these data demonstrate that
the PAD in the N-terminal region of tau is
both necessary and sufficient to induce in-
hibition of anterograde FAT.
PAD inhibits FAT through a PP1–GSK3
signaling cascade
We next evaluated whether FAT inhibi-
tion induced by the PADpeptide involved
activation of PP1 and GSK3 as observed
with 6D tau (above) and aggregated tau
(LaPointe et al., 2009). Again, coperfusion
of the PADpeptide with either I-2 (50 nM)
(Fig. 5A) or ING-135 (100 nM) (Fig. 5B) completely prevented
anterograde FAT inhibition. Anterograde (Fig. 5C) and retro-
grade (Fig. 5D) FAT rates observed after coperfusion of the tau
PAD peptide with either I-2 or ING-135 were indistinguishable
from those observed after perfusion of soluble WT tau.
The effect of the PAD peptide on the activity of endogenous
axoplasmic phosphatases was evaluated using a phosphatase ac-
tivity assay (Fig. 5E,F). In this assay, a recombinant GST-tagged
c-Jun construct was phosphorylated with p38 kinase in the pres-
ence of 32P-ATP for use as a phosphatase substrate. Isolated
axoplasms were perfused with radiolabeled c-Jun (32P-c-Jun),
and aliquots of the perfusates were collected at various time
points and separated by SDS-PAGE. Autoradiograph analysis
showed a marked reduction in 32P-c-Jun signal after 30 min of
incubation, indicating the action of axonal phosphatases. The
reduction was completely abolished by okadaic acid and, to a
lesser extent, by I-2, suggesting dephosphorylation of 32P-c-Jun
by axoplasmic serine-threonine phosphatases (Fig. 5E). Next,
two sister axoplasms were prepared from the same squid, and
each was perfused with 32P-c-Jun and either the 2–18 or scram-
bled 2–18 peptides. Consistent with results from vesicle motility
assays, 32P-c-Jun was dephosphorylated to a greater extent in
PAD peptide-perfused axoplasms than their scrambled peptide-
perfused counterpart (Fig. 5F), suggesting that the PAD peptide
induced activation of endogenous axoplasmic phosphatases.
Kinase activity assays were used to determine the effect of the
PAD peptide on axoplasmic GSK3. Sister axoplasms were treated
with PAD peptide or scrambled peptide, and then aliquots of
perfusate containing axoplasmic proteins were incubated with
32P-ATP and either a GSK3 (GSM peptide) or protein kinase C
(MARCKS peptide) substrate. A trend of elevated GSK3 activity
(	32%) relative to PKC activity ( p 0.28, paired t test; n 3)
was observed for axoplasms incubated with the PAD peptide
(mean 4.9
 2.5), compared with those incubated with scram-
bled peptide (mean 3.7
 1.7), which supports the results from
vesicle motility assays. Reduced sensitivity to changes in GSK3
activity may likely be a result of PAD affecting only a fraction of
all available axoplasmic GSK3 enzymes. Collectively, these data
indicate that PAD is both necessary and sufficient to inhibit an-
terograde FAT by activating the PP1–GSK3 cascade.
Disease-associated changes in tau cause inhibition of FAT
Together, the above data suggest that increased exposure of PAD
in the context of aggregated WT tau and 6D/6P tau isoforms,
results in PP1-GSK3 activation and anterograde FAT inhibition,
whereas PAD exposure is limited in soluble WT tau. Consistent
with this notion, a paperclip conformation has been shown for
soluble, monomeric WT tau (Jeganathan et al., 2006). This con-
formation involves intramolecular interactions between the C
terminus and the MTBR, and between the extreme N terminus
(containing PAD) and the C terminus. Folding of tau into the
paperclip conformation may therefore limit exposure of PAD,
preventing it from activating the PP1–GSK3 cascade. This model
predicts that disease-related taumodifications inmonomeric tau
that alter the paperclip conformation may result in abnormal
exposure of PAD and should be toxic to FAT. To test this possi-
bility, we evaluated the effects of two disease-associated forms of
tau, termed “AT8 tau” and “144–273 tau” (Fig. 1B,C), on FAT.
Pseudophosphorylation of tau at the AT8 epitope (comprised of
Ser199, Ser202, and Thr205) reduces the folding of the N terminus
into thepaperclip conformation(Jeganathanet al., 2008), suggesting
that phosphorylation of tau at these sites could increase PAD expo-
sure. To determine whether AT8 phosphorylated tau monomers
could inhibit anterograde FAT, we perfused AT8 pseudophospho-
rylated tau [Ser199Glu/Ser202Glu/Thr205Glu (AT8 tau)] (Fig.
1B) into isolated squid axoplasms. Soluble AT8 tau monomers
Figure 4. PAD is necessary and sufficient to trigger anterograde FAT inhibition. A, Perfusion of2–18 6D into isolated axo-
plasm did not affect FAT in either direction (black triangle, anterograde; gray triangle, retrograde).B, In contrast, perfusion of the
PAD peptide, which corresponds to amino acids 2–18 inWT tau, caused a reduction of anterograde, but not retrograde FAT rates.
C, A scrambled version of the PAD peptide was used as a control, and when applied to squid axoplasms did not affect FAT. D,
Quantitative analysis of FAT rates indicates that PAD peptide significantly inhibits anterograde FAT (one-way ANOVA, *p 0.01),
while deletion of the PAD sequence in 6D (2–18 6D) and scrambling the PAD peptide (Scram PAD) completely prevented
inhibition of anterograde FAT. E, Retrograde FAT rates were unaffected in all groups tested.
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inhibited anterograde FAT (Fig. 6A,C), while retrograde trans-
port was unaffected (Fig. 6A,D). These data indicate that phos-
phorylation of tau at the AT8 epitope, which is associated with
hyperphosphorylation of tau in AD and other tauopathies,
renders soluble monomeric tau capable of inhibiting antero-
grade FAT.
A novelmutation in the tau gene associatedwith a case of FTD
was recently reported (Rovelet-Lecrux et al., 2009). This tau mu-
tation results in deletion of amino acids 144–273 encompassing
the proline-rich domain and the first MTBR (144–273 tau)
(Fig. 1C). Deletion of these tau domains should result in consti-
tutive exposure of PAD because they play a pivotal role in the
intramolecular folding of the N terminus. Consistent with our
model, 144–273 tau monomers significantly inhibited antero-
grade FAT (Fig. 6B,C), while retrograde FAT remained unaf-
fected (Fig. 6B,D).Together, these data indicate that disease-
associated modifications and mutations in tau that increase
exposure of PAD promote activation of the PP1–GSK3 pathway
and inhibition of anterograde FAT.
Increased exposure of PAD is an early event in AD
Results from isolated axoplasm experiments suggested a molec-
ular basis for tau toxicity. To evaluate the relevance of these find-
ings in human disease, we generated a novel monoclonal
antibody, termed TNT1, which specifically recognizes PAD. The
TNT1 antibody exhibits a very high affinity (EC50  5.5 ng/ml)
forWT tau containing PAD (Fig. 7A) and does not react with tau
missing PAD (2–18 tau) in ELISAs [WT tau: mean absorbance
at 450 nm (A450) 2.4
 0.03;2–18 tau:
mean A450  0.003 
 0.004] and immu-
noblots (Fig. 7A). Using the TNT1 anti-
body, we examined the availability of PAD
inAD and control brains. First, we probed
samples of soluble and insoluble tau iso-
lated from the frontal cortex of control
and severe AD cases using immunoblots.
The pattern of TNT1 reactivity on West-
ern blots was consistent with that of tau
isolated fromhuman brain as indicated by
the Tau12 (Horowitz et al., 2004) and R1
tau antibodies (Berry et al., 2004) (two
well characterized tau-specific antibod-
ies), confirming the specificity of TNT1
for tau protein and not non-tau proteins
in human brains (Fig. 7B). Under these
denaturing conditions, TNT1 reacted
similarly with soluble tau from controls
and AD samples, as well as with insoluble
tau from AD samples (Fig. 7B).
To further explore the characteristics
of TNT1 reactivity, we analyzed soluble
and insoluble tau fractions using dot
blots, which like Western blots are solid-
state assays, but unlike Western blots the
proteins are not denatured. In dot blots,
TNT1 showed a significantly increased se-
lectivity for both soluble and insoluble tau
isolated from AD, as opposed to control
brains (Fig. 7C). The lack of distinction
between control and AD tau in denatur-
ing conditions by TNT1, but significant
selectivity for AD tau over control tau in
non-denaturing conditions, highlights
that TNT1 reactivity is indicative of PAD exposure, which is de-
pendent upon maintaining protein conformation. Thus, these
results suggest that PAD is more readily available in the native
state of tau derived from AD brains, compared with tau derived
from control brains, and TNT1 immunoreactivity can be used as
an indicator of PAD exposure.
Immunohistochemistry with TNT1 was performed on tissue
sections from controls (Braak stages I–II; n  4) and severe AD
(Braak stages V–VI; n  4) cases to determine when and where
PAD exposure occurs in the disease process. Qualitative evalua-
tion of sections from the entorhinal cortex (Fig. 7D) and hip-
pocampus (Fig. 7E), as well as the inferior and superior temporal
gyri (data not shown) indicated that TNT1 reactivity followed the
typical pattern of Braak staging (Braak and Braak, 1991). In age-
matched control cases, TNT1 diffusely labeled neurons in the
earliest stages of tau deposition (e.g., early pretangle neurons),
and a subset of these neurons contained small, darkly stained,
globular intracellular inclusions (Fig. 7F). A small number of
neurons in control cases exhibited strong TNT1 immunoreactiv-
ity of seemingly immature tangle-like inclusions that extended
into both apical and basal dendrites (Fig. 7F). With progression
into severe AD, there was a remarkable increase in the amount
of TNT1 immunoreactive inclusions (Fig. 7D,E), which in-
cluded neurofibrillary tangles (Fig. 7G), neuropil threads (Fig.
7G), and neuritic plaques (Fig. 7H ). These data indicated that
increased PAD exposure, as revealed by TNT1 immunoreac-
tivity, occurs early in AD and remains present throughout the
disease process.
Figure5. PADpeptide inhibits anterograde FAT by activation of the PP1–GSK3 cascade.A, Coperfusion of PADpeptidewith I-2,
a specific PP1 inhibitor, had no effect on anterograde (black triangle) or retrograde (gray triangle) FAT in squid axoplasm (compare
with Fig. 4B).B, Coperfusion of PAD peptidewith ING-135, a specific GSK3 inhibitor, similarly prevented inhibition of anterograde
FAT by PAD. C, Quantitative analysis of FAT reveals that PAD peptide alone specifically and significantly inhibits anterograde FAT
(one-way ANOVA, *p 0.01), while addition of either PP1 or GSK3 inhibitors completely prevented the reduction in anterograde
FAT rates induced by the PAD peptide. D, Retrograde FAT rates were unaffected in all groups tested. E, 32P-c-Jun (a phosphatase
substrate) undergoes dephosphorylation by endogenous axoplasmic phosphatases after 30 min. Axoplasms were perfused with
32P-c-Jun alone (Ctrl) or with 32P-c-Jun and either okadaic acid (OK, 1M) or I-2 (400 nM). Aliquots were taken immediately after
perfusion (0) and 30min later (30), and analyzed by autoradiography. F, 32P-c-Junwas dephosphorylated to a greater extent in
PAD-perfused axoplasms than its scrambled PAD-perfused “sister” counterpart, suggesting increased activation of endogenous
axoplasmic phosphatases by PAD. Sister axoplasms from the same squid were perfused with 32P-c-Jun and either scrambled PAD
(Scr) or PAD peptides, and analyzed by autoradiography (n 2 sets of sister axoplasms).
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We next determined the relationship between PAD exposure
andAT8 phosphorylation in tau since thismodification rendered
soluble tau monomers toxic to FAT (see above). Tissue sections
from the hippocampus of controls (Braak stages I–II;n 4),mild
AD (Braak stages III–IV; n  5), and severe AD (Braak stages
V-VI; n 4) were double stained with TNT1 and AT8 antibodies
using immunofluorescence (Fig. 7I–K). Qualitative observations
indicated that TNT1 immunoreactivity might appear slightly be-
fore the development of AT8 phosphorylation in the course of
AD. Numerous TNT1-positive structures (e.g., cell bodies and
threads) in control cases (Fig. 7I) did not appear to be AT8 pos-
itive. As pathology progressed intomild AD (Fig. 7J), the amount
of both TNT1 and AT8 increased. Finally, in severe AD stages
(Fig. 7K) both TNT1 and AT8 were abundant and exhibited
nearly complete colocalization. It should be noted that when
present, AT8 immunoreactivity was almost always colocalized
with TNT1 in all cases analyzed. Together, these data suggest
that increased PAD exposure represents an early event in AD
pathogenesis and that AT8 may not be required for PAD ex-
posure in situ.
Discussion
Recently, we demonstrated that WT tau aggregates inhibit an-
terograde FAT by activating a PP1–GSK3 signaling cascade
through a mechanism requiring the N terminus of tau (LaPointe
et al., 2009). Extending those observations, we have identified a
tau domain comprised of amino acids 2–18 that is both necessary
and sufficient to activate the PP1–GSK3 cascade and inhibit an-
terograde FAT. These effects suggest a novel function for tau and
define a new functional motif in tau, the PAD. Inhibition of
anterograde FATby the 6D and 6P isoforms of tau and a synthetic
PAD peptide demonstrates that this effect does not require tau
binding to microtubules or tau aggregation. Our results demon-
strate that exposure of PAD is a critical factor mediating the
ability of pathogenic forms of tau to inhibit FAT. Consistent with
this hypothesis, two disease-associated taumodifications that in-
crease PAD exposure inhibited anterograde FAT as soluble
monomers. Further supporting the role of PAD exposure as an
important disease-related event, the novel PAD-specific antibody
TNT1 selectively labeled both soluble and insoluble tau isolated
from AD brains, but not that from controls. Moreover, qualita-
tive observations of TNT1 immunoreactivity in humanAD tissue
sections suggested that PAD exposure represents an early patho-
logical event that closely associates in time with AT8 phosphory-
lation. These data have important implications regarding the role
of tau in disease pathogenesis and provide a mechanism through
which disease-associated modifications and/or mutations in tau
lead to a toxic gain-of-function in AD and other tauopathies.
The demonstration that PAD is a region within tau that can
modulate the PP1–GSK3 cascade has significant implications for
tau pathology and suggests a novel biological role for tau regulat-
ing the activity of phosphotransferases and anterograde FAT (Fig.
8). Tau has been shown to target PP1 to microtubules and can
directly interact with PP1 (Liao et al., 1998). Amino acids 5–8,
located within PAD, comprise one of the proposed PP1 binding
sites in tau (Liao et al., 1998). Additionally, tau and GSK3 have
been copurified as part of a high-molecular-weight complex in
associationwith purifiedmicrotubules (Sun et al., 2002). Thus, in
addition to microtubule stabilization, tau may bind and target
phosphotransferases to the vicinity ofmicrotubules (Shahani and
Brandt, 2002) and regulate FAT through modulation of these
enzymes (Fig. 8A), a functional scheme that may be disrupted in
disease (Fig. 8B).
Deficits in FAT have previously been implicated in the neuro-
nal dysfunction associated with dysferopathies such as AD,
non-AD tauopathies, and other neurodegenerative diseases
(Morfini et al., 2002a, 2009; Roy et al., 2005). In AD brains,
dystrophic neurites, synaptic loss, and protein mislocalization
(Scheff et al., 1990; Dessi et al., 1997) are all consistent with FAT
deficits. Accordingly, studies in various animalmodels of AD and
tauopathies have reported alterations in axonal transport (e.g.,
axonal swellings, synaptic loss, and impaired vesicle transport)
(for review, see Higuchi et al., 2006). Interestingly, tau appears to
play a critical role in amyloid--mediated axonal transport dis-
ruption, as genetically removing taumitigates the effects of treat-
ing neurons with amyloid- oligomers (Vossel et al., 2010).
These studies suggested a link among tau, axonal dysfunction,
and neurodegenerative disease; however, until this report the
molecular mechanisms linking deficits in FAT to disease-related
modifications of tau had remained unclear (Morfini et al.,
2002a).
Several studies on the role for tau in axonal transport dysfunc-
tion proposed a mechanism involving direct interference of tau
with the binding of conventional kinesin to microtubules
(Ebneth et al., 1998; Seitz et al., 2002; Vershinin et al., 2007).
However, overexpression of human tau in transgenic mice did
not affect FAT rates in the optic nerve (Yuan et al., 2008), and
levels of solubleWT tau 20-fold greater than endogenous levels of
tau had no effect on FAT in squid axoplasm (Morfini et al., 2007).
Studies on aggregated tau (LaPointe et al., 2009) and the current
data provide evidence for an alternativemechanism independent
of microtubule binding that does not require aggregation. Spe-
cifically, many of the tau species examined in these studies do not
effectively bind microtubules (e.g., tau aggregates, 6D/6P tau,
Figure 6. Taumonomers with disease-associatedmodifications inhibit anterograde FAT. A,
Perfusion of squid axoplasm with soluble tau monomers containing mutations S199E, S202E,
and T205E (phosphomimicking the AT8 epitope seen in hyperphosphorylated tau; AT8 tau)
causes a reduction in anterograde FAT (black triangle), but not retrograde (gray triangle) FAT.B,
Similarly, perfusion of squid axoplasm with soluble 144–273 tau monomer (mimicking a
deletion mutation associated with a case of FTD) results in a reduction in anterograde FAT, but
not retrograde FAT. C, Quantitative analysis of FAT rates demonstrates that AT8 taumonomers
and144–273 taumonomers significantly inhibit anterograde FAT, when comparedwithWT
taumonomers (one-way ANOVA, *p 0.01).D, Retrograde FAT rates remained unaffected for
all pathogenic tau monomers tested.
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Figure 7. PAD immunoreactivity in AD brains. A, An ELISA titer of the TNT1 antibody using recombinant WT tau indicates a LogEC50 of 5.25 or a 1:180,000 dilution of a 1 mg/ml stock (final
concentration, 5.5 ng/ml). TNT1does not reactwith tau lacking PAD (amino acids 2–18;2–18) in immunoblots.B, TNT1 labels enriched soluble tau from the frontal cortex of both control (Con Sol)
andADbrains (AD Sol) aswell as purified paired helical filament tau (ADPHF) fromAD frontal cortex in denaturing conditions onWestern blots. Comparison of TNT1blotswith Tau12 andR1 tau blots
clearly indicates that TNT1 recognizes tau proteins and not other proteins in human brains. C, Dot blots of TNT1 under non-denaturing conditions. TNT1 preferentially labels soluble and PHF tau
isolated from AD brains as opposed to tau isolated from control brains, indicating that PAD-exposed tau conformations are more abundant in AD. Quantification of both soluble and insoluble tau
fractions is depicted as TNT1:Tau12 optical density (OD) ratios in the bar graph; Tau12was used tomeasure total tau. *p 0.05, unpaired t test.D, E, TNT1 immunohistochemistry in the entorhinal
cortex (D) and hippocampus (CA1 region; E) of human Braak stages I–II (control) or V–VI (severe AD) cases. Spatial and temporal patterns of TNT1 staining followed those of Braak staging, starting
in the entorhinal cortex (D) and then appearing in the hippocampus (E) before involving temporal cortical gyri in later stages (data not shown). Scale bars, 100m. F, TNT1 staining in Braak stage
I–II cases. TNT1 diffusely labeled the cytoplasmof pretangle CA2 neurons in the very early stages of inclusion formation (arrow). A subset of diffusely stained neurons contained globular cytoplasmic
inclusions (filled arrow). A few neurons contained strongly labeled seemingly less mature tau inclusions that extended into the basal (arrowhead) and apical (black triangle) dendrites. G, H, TNT1
in Braak stages V–VI; note that large amounts of the classical tau inclusions, neurofibrillary tangles (arrow; G), neuropil threads (black triangle; G) and neuritic plaques (*; H ), were present in the
regions analyzed (CA1 shown). Scale bars, 20m. I–K, Representative images of TNT1 (red) and AT8 (green) double-label immunofluorescence in the hippocampus (CA1/CA2 region). I, The TNT1
epitope appears to precede that of AT8 in controls cases (Braak stages I–II). J, Both TNT1 and AT8 continue to accumulate in mild AD (Braak stages III–IV). K, TNT1 and AT8 appear with nearly
complete colocalization in severe AD (Braak stages V–VI). Note that when present, AT8 extensively colocalizes with TNT1 at all Braak stages. Scale bars, 50m.
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PAD peptide, and FTD 144–273 tau),
and many were used as monomers (e.g.,
6D/6P tau, PAD peptide, FTD 144–273
tau, and AT8 tau). Moreover, we have es-
tablished that tau inhibits anterograde
FAT by activating the PP1–GSK3 cascade
with nearly all of the tau species tested
thus far. Together, these data clearly dem-
onstrate that tau-mediated disruption of
anterograde FAT via the PP1–GSK3 cas-
cade is independent of microtubule bind-
ing and does not require aggregation.
Based on our prior studies (LaPointe et
al., 2009), it was unclear why monomeric
WT tau failed to affect FAT even though
the PADmotif was present. Tau was orig-
inally thought to exist in an extended ran-
dom coil state based on spectroscopic
studies (Mandelkow et al., 2007). How-
ever, fluorescence resonance energy
transfer studies indicated that solublemo-
nomericWT tau adopts a folded paperclip
conformation (Jeganathan et al., 2006,
2008), that may prevent PAD from acti-
vating the PP1–GSK3 cascade. Con-
versely, conformations of tau that
increase exposure of PAD should pro-
mote inhibition of anterograde FAT.
We tested this hypothesis using nu-
merous forms of tau in which the accessi-
bility of PAD is increased. In tau
aggregates, both termini of tau are be-
lieved tomaintain a random coil structure
extending from the filament core formed
by theMTBRs (Barghorn et al., 2004). Ev-
idence also suggests aggregated tau favors
an Alz50-type conformation (Carmel et
al., 1996), in which the N terminus is in
close contact with the MTBRs. However, the results presented
here suggest that the extreme N terminus of tau remains accessi-
ble in aggregated tau. The 6D and 6P isoforms of tau lack the
MTBRs and C terminus (Luo et al., 2004) necessary for the pa-
perclip conformation, leaving PAD constitutively available, and
the PAD peptide is composed of only amino acids 2–18. Simi-
larly, a recombinant pseudophosphorylated AT8 tau exhibits re-
duced folding of the N terminus into the paperclip conformation
(Jeganathan et al., 2008). Finally, deletion of amino acids 144–
273 in the FTD tau construct should dramatically reduce or elim-
inate the ability of the N terminus to fold into the paperclip, as
this deletion removes the proline-rich hinge region involved in
N-terminal folding. Consistent with our hypothesis, all of
these “PAD-exposed” tau species inhibited anterograde FAT;
thus, exposure of PAD provides a common mechanism of
toxicity for biochemically heterogeneous forms of pathogenic
tau.
Highlighting the relevance of results obtained from studies in
isolated squid axoplasm, a PAD-specific antibody (TNT1) that pref-
erentially recognizes disease-related forms of tau confirmed the im-
portance of PAD exposure in human disease pathogenesis. Data
obtained from immunostaining studies in human brain tissue indi-
cated that increasedPADexposureoccurs very early in theprocessof
tau inclusion formation and that AT8 is closely associated with
PAD exposure during AD progression. Importantly, quantitative
analyses are required to confirm our observations and conclu-
sively determine the time course of PAD exposure in relation to
other tau modifications during the progression of disease in hu-
mans. However, in combination with our squid axoplasm data, it
is reasonable to assume that AT8modification abundantly found
in AD (Braak et al., 1994) and other tauopathies (Takahashi et al.,
2002; Sakai et al., 2006; Shiarli et al., 2006) may facilitate PAD
exposure and tau-mediated FAT dysfunction in situ. Addition-
ally, our data suggest a cyclical relationship between PAD expo-
sure and AT8 phosphorylation in which the AT8 modification
might result, at least in part, from the increased GSK3 activation
triggered by abnormally exposed PAD, since S199, S202, and
T205 are GSK3 phosphorylation sites.
Since neurons are thought to maintain function for years
while bearing tau inclusions (Morsch et al., 1999), it is reasonable
to assume the existence of compensatorymechanisms that render
pathogenic forms of tau innocuous. Phosphorylation of tyrosine
18 (within PAD) by kinases such as fyn (Lee et al., 2004) or
N-terminal cleavage of tau (Horowitz et al., 2004; Sengupta et al.,
2006) may represent such protective mechanisms. Jeganathan et
al. (2008) demonstrated that combinations of phosphorylation
events have different effects on tau folding. While AT8 alone
reduces N-terminal folding, AT8 in combination with the AT100
(T212/S214) and PHF-1 (S396/S404) phosphorylation epitopes
causes tau to fold into a more compact paperclip conformation.
Figure 8. Proposed role of PAD in anterograde fast axonal transport regulation and in axonal transport dysfunction in disease.
A, Tau is normally localized to microtubules where, in addition to stabilizing microtubules, it may regulate local cargo delivery
through PAD-mediated activation of the PP1–GSK3 cascade. When tau is folded into the paperclip conformation, membrane-
bound cargoes are transported by conventional kinesin alongmicrotubules because PAD is hidden. In contrast, cargo is delivered at
appropriate locations where tau is in an extended conformation and PAD is exposed. The exposure of PAD activates PP1-GSK3,
leading to phosphorylation of kinesin light chains and release of cargoes. B, In disease states, tau aggregations and/or modifica-
tions expose PADs in tau that no longer binds tomicrotubules, promoting aberrant activation of the PP1–GSK3 cascade, increased
inhibition of anterograde FAT, and ultimately neuron dysfunction/degeneration. Abnormal presentation of the biologically active
PADmotif represents a critical factor in determining whether disease-associated forms of tau inhibit anterograde FAT.
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Regulation of tau conformation through protein–protein or in-
traprotein interactions as well as through modifications like
phosphorylation or proteolysis might be part of a complex set of
events that regulate tau function, includingmicrotubule binding,
modulation of phosphotransferase-based signaling pathways,
and anterograde FAT.
Although tau has been recognized as a potential therapeutic
target in AD and tauopathies, choosing therapeutic targets and
testable outcome measures has proven difficult without an un-
derstanding of the mechanisms through which tau can influence
disease progression. The identification of PAD and its effects on
phosphotransferase activity and FAT regulation allow us to pro-
pose specific targets for intervention. For instance, reducing the
activities of PP1 and/or GSK3 may reduce the toxic potential of
pathogenic forms of tau. Alternatively, therapeutic strategies
aimed at directly blocking PAD exposure and preventing it from
activating the PP1–GSK3 cascade may provide yet another viable
point of intervention.
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